RSS Feeds
Angiotensin-Converting Enzyme Inhibitors for Secondary Erythrocytosis
- Fadi Fakhouri, MD;
- Jean-Pierre Grünfeld, MD;
- Olivier Hermine, MD, PhD; and
- Richard Delarue, MD
- From Hôpital Necker, 75015 Paris, France.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Secondary erythrocytosis is related to an inappropriate secretion of erythropoietin. It has been reported in the setting of chronic hypoxia, neoplasia, and renal transplantation and more rarely in patients with cystic renal diseases. Angiotensin-converting …
This 100-word excerpt has been provided in the absence of an abstract.
